Asset profile
dazodalibep · Amgen (AMGN)
- Indication
- moderate-to-severe systemic Sjögren's disease
Company
AMGNAmgen
AMGNAmgenAmgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer the…
On the calendar
11
Dec 2029
Dec 11, 2029
in 1146 days
AMGNAmgenTimeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT06747949 | Phase 3 | Recruiting | Dec 11, 2029 | 844 | 31 of 174 sites in the United States |
| NCT06104124 | Phase 3 | Completed | Jul 23, 2026 | 651 | 37 of 206 sites in the United States |
| NCT06245408 | Phase 3 | Active, not recruiting | Oct 22, 2026 | 434 | 41 of 194 sites in the United States |
More from Amgen
Other drugs and candidates from the same company tracked in this sector.
evolocumabadults with established atherosclerotic cardiovascular disease or at high risk of developing it, to reduce cardiovascular risk by lowering LDL-Ctarlatamabextensive-stage small cell lung cancer (ES-SCLC) after progression on or after first-line platinum-based chemotherapyteprotumumab-trbwmoderate-to-severe active Thyroid Eye Diseasetezepelumab-ekkoeosinophilic esophagitis